272. 進行性骨化性線維異形成症 Fibrodysplasia ossificans progressiva Clinical trials / Disease details
臨床試験数 : 40 / 薬物数 : 36 - (DrugBank : 6) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04818398 (ClinicalTrials.gov) | April 1, 2021 | 24/3/2021 | Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects | Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects | Fibrodysplasia Ossificans Progressiva | Drug: DS-6016a;Drug: Placebo | Daiichi Sankyo Co., Ltd. | NULL | Active, not recruiting | 20 Years | 45 Years | Male | 48 | Phase 1 | Japan |